WIDE MOAT STOCKS & COMPETITIVE ADVANTAGES

Checking

 

Elevance Health, Inc. ELV

NYSEHealthcare servicesFinancials to Sep 30, 2026 · Updated Nov 11, 2026

On Stock Analysis · affiliate link
ELV financials
Moat score
77
ROIC
9.9%
P/E
18.1
Incl. −$935M one-offs
EV/EBIT
17.6
Incl. −$935M one-offs
FCF yield
7.0%
Dividend yield
1.6%
Market cap
$92.8B

Moat ranks

Score rankTied #182 of 396
Durabilitydurable
Market structureOligopoly
Pricing powermoderate

Balance sheet

9/30/26
$BDec 31Sep 30
Cash9.110.3
Securities26.625.3
Long-term securities0.01.2
Restricted cash1.50.5
Debt31.930.8
Net cash3.96.1
Equity43.944.7
Leverage
Debt / EBITDA
4.79×
Debt / equity
0.69×
Leases (12/31/25)
$660M
Capital
Diluted shares
218M
Book value / share
$205.34
Price / book
2.1×
Net cash / share
$28.26
Market cap
$92.8B
Enterprise value
$86.7B

Per-share record

Fiscal years and TTM
Scale
$0$250$500$750$1,000'16'17'18'19'20'21'22'23'24886.58'25927.53TTM
Revenue per shareCash flow per share

Key indicators

Latest: Q3 '26
IndicatorLatestVs year agoLast 8 quarters
Revenue growth1.4%-11.0 pts
Operating margin2.3%+0.0 pts
FCF margin1.9%+0.4 pts
Capex / revenue0.5%-0.2 pts
Medical members44.9M-1%
Adjusted prescriptions82.6M-3%
Carelon Services consumers91.0M-7%
Benefit expense ratio90.6%-0.7 pts
Gross margin–––

Margins and growth from reported quarters; company KPIs as reported in results releases.

About ELV

Elevance sells employer, individual and government health coverage, pharmacy benefits through CarelonRx, and clinical and administrative services through Carelon Services. Health Benefits supplies about 84% of external segment revenue.

Revenue mix
Health Benefits 84.1%CarelonRx 12.3%Carelon Services 3.6%
  • Concession License

    BCBSA license agreements grant (largely) exclusive rights to use Blue Cross / Blue Shield names and marks in assigned territories.

  • Brand Trust

    The Blue brands give local recognition and access to an established national network.

  • Data Workflow Lockin

    Replacing claims adjudication, formulary data, pharmacy networks and member services requires a coordinated payer transition.

  • Suite Bundling

    Distribution advantage from selling PBM services to Elevance-affiliated health plans plus external clients; supports cross-sell with medical and other Carelon services.

Timeline
  1. Nov 10, 2026

    Elevance reaffirmed its 2026 EPS floors of $22.00 GAAP and $29.00 adjusted on November 10, with benefit expense ratio guidance of 90.2% plus or minus 50 basis points. This is a forecast, not a realized underwriting result. Source: https://www.sec.gov/Archives/edgar/data/1156039/000115603926000074/elv-20261110.htm

  2. Oct 1, 2026

    Elevance announced its 2027 Medicare Advantage offerings, keeping local brands and coordinated services as its enrollment proposition for the new plan year.

  3. Sep 10, 2026

    Elevance reaffirmed full-year earnings and medical-cost guidance, leaving the expected recovery dependent on premium repricing and claims performance.

  4. Jul 13, 2026

    CMS closed the risk-adjustment enforcement process after required data corrections; the threatened sanctions were not imposed, but repayment obligations remained.

  5. Mar 31, 2026

    Elevance appointed new government-business and Carelon leaders to improve clinical execution, financial oversight and coordination with the health plans.

Financial record

Fiscal year2016201720182019202020212022202320242025TTMTrendChange 2016–25
Per share ($)
Revenue316.53336.22348.62400.36479.23561.75644.95721.74760.03886.58927.53+12.1%/yr
Cash flow12.2015.6314.4923.2842.0333.8934.5933.9624.9419.1034.91+5.1%/yr
Earnings9.2114.3514.1918.4717.9824.9524.2825.2225.6825.2123.62+11.8%/yr
Free cash flow10.0212.679.9119.1538.0129.4929.8528.5019.5414.1329.94+3.9%/yr
Capex2.182.954.574.144.014.404.745.465.394.974.97+9.6%/yr
Dividends2.552.632.943.143.754.475.065.886.476.816.89+11.5%/yr
Book value93.6398.97108.03121.89130.55146.25149.27165.57177.39195.38205.34+8.5%/yr
Diluted shares (M)268268264260254247243237233225218-1.9%/yr
Totals ($B)
Revenue84.990.092.1104.2121.9138.6156.6171.3177.0199.1201.8+9.9%/yr
Operating income4.64.05.15.76.07.17.57.67.36.64.9+4.0%/yr
Net income2.53.83.84.84.66.25.96.06.05.75.1+9.7%/yr
Free cash flow2.73.42.65.09.77.37.26.84.63.26.5+1.9%/yr
Buybacks0.02.01.71.72.71.92.32.72.92.62.2–
Dividends0.70.70.80.81.01.11.21.41.51.51.5+9.3%/yr
Net cash7.35.33.36.010.510.110.211.23.43.96.1−$3.4B
Margins & returns (%)
Operating margin5.44.45.55.44.95.14.84.44.13.32.4-2.1 pts
Net margin2.94.34.14.63.84.43.83.53.42.82.5-0.1 pts
FCF margin3.23.82.84.87.95.24.63.92.61.63.2-1.6 pts
ROIC20.515.016.017.521.021.822.921.515.313.19.9-7.5 pts
Return on equity9.814.513.115.213.817.116.315.214.512.911.5+3.1 pts
Stock pay % of revenue0.20.20.20.30.20.20.20.20.10.10.1-0.1 pts
Capex % of revenue0.70.91.31.00.80.80.70.80.70.60.5-0.1 pts

Change uses 2016 and 2025 only: compound annual growth for amounts, points for margins and returns, and the change in amount for net cash. A dash means no 2016 base. Trend shows the fiscal years.

TTM = four quarters to Sep 30, 2026. Per-share values use diluted weighted shares.ROIC = operating income × (1 − 20.5% tax rate, the company's own over three fiscal years excluding one-offs) ÷ (equity + debt − cash and current securities). Returns show a dash when their base is negative or under 10% of revenue. Free cash flow = operating cash flow − capex. Debt is all borrowings; net cash counts long-term securities and excludes leases.

Moat

Moat scorecard

Moat score77
Strength
Confidence
Structure
Oligopoly
Durability
durable
Trajectory
stable
Pricing power
moderate
Segments
  • Health Benefits84.1%
    2 claims
  • CarelonRx12.3%
    2 claims
  • Carelon Services3.6%
    1 claim

Moat claims

Applies to
Health Benefits
Confidence
Durability
durable
Trajectory
stableas of Oct 7, 2026
Why it holds

BCBSA license agreements grant (largely) exclusive rights to use Blue Cross / Blue Shield names and marks in assigned territories.

Why stable

Blue brand licenses still cover 14 states, while the 80% local revenue requirement and capital standards remain; second Blue bids for selected national employers limit the exclusivity.

Indicators
  • Medical members44,882,000-1%
  • Benefit expense ratio90.6%-0.7 pts
Risks
  • BCBSA rule changes weakening exclusivity
  • License termination from non-compliance or change-of-control constraints
  • Antitrust/settlement changes enabling more second-bid competition for national accounts

Profile change log

  1. Nov 11, 2026 · business change

    Elevance reaffirmed its 2026 EPS floors of $22.00 GAAP and $29.00 adjusted on November 10, with benefit expense ratio guidance of 90.2% plus or minus 50 basis points. This is a forecast, not a realized underwriting result. Source: https://www.sec.gov/Archives/edgar/data/1156039/000115603926000074/elv-20261110.htm

  2. Nov 11, 2026 · analyst revision

    Reconciled current-quarter operating evidence and guidance; added the latest demand and capital-allocation counterevidence without changing moat strength ratings.

  3. Oct 7, 2026 · analyst revision

    Replaced Q2 segment revenue weights with FY2025 external revenue and removed profit shares that excluded corporate costs. Reduced Blue license strength from 5 to 4 because rights protect brand use rather than the insurance market. Added trajectories, operating evidence, management and a balanced debate.

  4. Oct 7, 2026 · business change

    Elevance announced its 2027 Medicare Advantage offerings, keeping local brands and coordinated services as its enrollment proposition for the new plan year.

  5. Oct 7, 2026 · business change

    Elevance reaffirmed full-year earnings and medical-cost guidance, leaving the expected recovery dependent on premium repricing and claims performance.

  6. Oct 7, 2026 · business change

    CMS closed the risk-adjustment enforcement process after required data corrections; the threatened sanctions were not imposed, but repayment obligations remained.

  7. Oct 7, 2026 · business change

    Elevance appointed new government-business and Carelon leaders to improve clinical execution, financial oversight and coordination with the health plans.

  8. Oct 7, 2026 · business change

    CMS threatened Medicare Advantage enrollment and marketing sanctions over historical risk-adjustment data, creating a remediation requirement and repayment exposure.

  9. Oct 7, 2026 · business change

    The Blue provider antitrust settlement took effect, requiring payments and changes to provider contracting, prompt payment and BlueCard technology.

  10. Oct 7, 2026 · business change

    Selected large national employers gained a second Blue plan bid under the subscriber antitrust settlement, increasing competition within the Blue system.

  11. Oct 7, 2026 · business change

    Elevance bought CareBridge, extending Carelon’s home and community-based care for Medicaid and dual-eligible members.

  12. Oct 7, 2026 · business change

    Elevance invested $2.580bn in Mosaic Health with Clayton, Dubilier & Rice, creating a minority partnership for care delivery and provider enablement.

  13. Oct 7, 2026 · business change

    Elevance bought Paragon Healthcare, adding infusion centers and specialty pharmacy services to CarelonRx.

Industry & peers

Peer map

0%10%20%30%40%50%60708090100Moat scoreELV
No peer numbers yet

Peers appear on the map as their numbers are collected.

U.S. health insurance and managed care

As of Oct 7, 2026
OligopolyLow cyclicality

Medical insurance and administration for employer, individual, Medicare Advantage and Medicaid plans in the United States, including access to provider networks and self-funded employer administration. Excludes pharmacy benefit management sold separately, life insurance and providers’ own care-delivery revenue.

  1. UnitedHealth Group
  2. Elevance Health
  3. Humana
  4. Centene
StocksMoatGross m.Op. m.
ELV77–2.4%
Industry median577––
Sector median557661.5%17.3%
All stocks median3987653.1%20.0%

Moat medians cover every stock. Margin medians count only stocks with collected numbers and need at least three.

Drivers & risks

Demand drivers
  • Annual premium repricing can offset higher hospital, physician and drug costs; state Medicaid rates may catch up more slowly than commercial premiums.
  • Aging expands Medicare demand, while eligibility reviews and coverage rules determine Medicaid enrollment and the risk mix.
  • Employers buy network breadth, administration and total cost, so local provider relationships matter even when national carrier names are well known.
  • Higher interest rates can improve income on insurer investments, while changes in bond values and investment returns can obscure health-plan profit. Domestic U.S. premiums create little direct currency exposure.
Risks
  • Medical utilization and provider-price inflation can outrun annual pricing; losses can persist even when premium revenue rises.
  • Reduced subsidies or stricter Medicaid eligibility can remove healthier members and worsen the remaining risk pool.
  • Medicare coding audits, repayment demands and quality ratings change reimbursements and can restrict new enrollment.
  • Local concentration attracts antitrust intervention; second Blue bids and provider settlement requirements reduce incumbent protections.
  • A weak labor market reduces employer enrollment and shifts people between employer coverage, exchanges and Medicaid.

Bulls & bears

Key question · as of Oct 7, 2026

Can premium repricing and Carelon cost control rebuild underlying profit while retaining members and external clients, after medical inflation and Medicare repayment costs?

Arguments

4 forFaded: weakening or settled6 against

What to watch

  1. 1Benefit expense ratio and Health Benefits operating gain
  2. 2Medical members and CarelonRx adjusted prescriptions
  3. 3Carelon Services external revenue, consumers served and operating gain
  4. 4CMS repayment liability and parent cash available for dividends

Next check: Next reported quarter and subsequent issuer announcements: Benefit expense ratio, membership and earnings excluding non-operating items. The next release date is not inferred from the prior reporting calendar.

Sources: company filings and dated sources collected for Find My Moat; market cap as of Nov 10, 2026. Not investment advice.

Cite or reuse this data

Free to reuse, commercially too, with a credit link. See the data license.

Moat Score 77/100 by <a href="https://www.findmymoat.com/stocks/XNYS:ELV">Find My Moat</a> (as of September 2026)

Curation & Accuracy

This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).

Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.